DaVita Inc. (NYSE:DVA) Receives Average Rating of “Hold” from Analysts

DaVita Inc. (NYSE:DVA) has received an average rating of “Hold” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $199.1667.

Several equities analysts have weighed in on DVA shares. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. Truist Financial increased their price objective on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research note on Friday, May 8th. TD Cowen lifted their price objective on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. UBS Group upped their target price on shares of DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Barclays lifted their price target on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th.

DaVita News Roundup

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita was added to Zacks’ list of top growth stocks and a “Strong Buy” group for July 2, suggesting improving momentum and favorable earnings estimate trends. Best Growth Stocks to Buy for July 2nd
• Positive Sentiment: Unusual options activity showed a large spike in call buying, which can signal that traders expect more upside in the near term.
• Positive Sentiment: DaVita expanded its integrated kidney care platform with AI tools for dialysis care, a development that could improve care efficiency and strengthen its long-term growth story. DaVita (DVA) Expands Integrated Kidney Care With AI Tools For Dialysis Care
• Positive Sentiment: DaVita was also highlighted by Zacks as one of five non-AI S&P 500 stocks that surged more than 30% in the first half of 2026 and still have momentum heading into the second half. Top 5 Non-AI S&P 500 Stock Picks for 2H 2026 That Have Surged in 1H
• Neutral Sentiment: Some valuation-focused commentary cautioned that while the stock has performed strongly, it may be considered overvalued based on GF Value measures. DaVita Inc (DVA) Stock Up 3.0% but GF Value Says Overvalued — GF Score: 88/100

Insider Activity at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their position. The SEC filing for this sale provides additional information. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DaVita

Several institutional investors have recently bought and sold shares of DVA. CX Institutional raised its stake in shares of DaVita by 7.7% in the 2nd quarter. CX Institutional now owns 2,480 shares of the company’s stock valued at $552,000 after acquiring an additional 178 shares during the period. Cozad Asset Management Inc. purchased a new stake in shares of DaVita in the first quarter worth about $212,000. Western Wealth Management LLC purchased a new stake in shares of DaVita in the first quarter worth about $60,000. Edgestream Partners L.P. acquired a new stake in shares of DaVita in the first quarter valued at about $398,000. Finally, Kentucky Retirement Systems purchased a new stake in shares of DaVita during the 1st quarter valued at about $2,240,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Price Performance

DVA traded down $0.12 during midday trading on Friday, reaching $234.79. 830,603 shares of the company’s stock were exchanged, compared to its average volume of 802,619. DaVita has a 1-year low of $101.00 and a 1-year high of $236.51. The stock has a market capitalization of $15.07 billion, a PE ratio of 21.78, a P/E/G ratio of 0.77 and a beta of 0.88. The business’s 50-day moving average price is $196.44 and its 200 day moving average price is $156.31.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same period in the prior year, the business earned $2.00 earnings per share. The company’s quarterly revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts expect that DaVita will post 15.07 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.